PE20231941A1 - Compuestos de oxoisoindolina sustituidos con piridinilo - Google Patents
Compuestos de oxoisoindolina sustituidos con piridiniloInfo
- Publication number
- PE20231941A1 PE20231941A1 PE2023002812A PE2023002812A PE20231941A1 PE 20231941 A1 PE20231941 A1 PE 20231941A1 PE 2023002812 A PE2023002812 A PE 2023002812A PE 2023002812 A PE2023002812 A PE 2023002812A PE 20231941 A1 PE20231941 A1 PE 20231941A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- oxoisoindoline
- pyridinyl substituted
- methylnicotinonitrile
- dioxopiperidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical group [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- JIRKNMRIEJWARS-UHFFFAOYSA-N CC(C=C(C(CN1C(CCC(N2)=O)C2=O)=C2)C1=O)=C2C(C=C1C)=NC(N)=C1C#N Chemical compound CC(C=C(C(CN1C(CCC(N2)=O)C2=O)=C2)C1=O)=C2C(C=C1C)=NC(N)=C1C#N JIRKNMRIEJWARS-UHFFFAOYSA-N 0.000 abstract 1
- JNQZDBAKBFBIII-UHFFFAOYSA-N CC1=CC(C(C(C)=C2CN3C(CCC(N4)=O)C4=O)=CC=C2C3=O)=NC(N)=C1C#N Chemical compound CC1=CC(C(C(C)=C2CN3C(CCC(N4)=O)C4=O)=CC=C2C3=O)=NC(N)=C1C#N JNQZDBAKBFBIII-UHFFFAOYSA-N 0.000 abstract 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- -1 pyridinyl-substituted oxoisoindoline Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
La presente invencion se refiere a un compuesto de formula I, o una sal del mismo, en donde: R1 es NH2 o NH(CH3); cada R2 es independientemente F, Cl, CN, alquilo C1-C4, entre otros; cada R4 es independientemente F, Cl, CH3, CH2F, entre otros; R6 es hidrogeno, alquilo C1-C2 o fluoroalquilo C1-C2; m es 0 a 3; n es 0 a 3; con la condicion de que cuando R6 es hidrogeno m es 1 a 3. Son compuestos especificos: 2-amino-6-(2-(2,6-dioxopiperidin-3-il)-4-metil-1 oxoisoindolin-5-il)-4-metilnicotinonitrilo, 2-amino-6-(2-(2,6-dioxopiperidin-3-il)-6-metil-1-oxoisoindolin-5-il)-4-metilnicotinonitrilo, entre otros. Tambien se refiere a una composicion farmaceutica. Los compuestos de la invencion son derivados de oxoisoindolina sustituidos con piridinilo que inhiben la proteina Helios, siendo utiles en el tratamiento de trastornos proliferativos tales como cancer e infecciones virales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111016193 | 2021-04-06 | ||
| IN202111022098 | 2021-05-17 | ||
| PCT/US2022/023387 WO2022216644A1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231941A1 true PE20231941A1 (es) | 2023-12-05 |
Family
ID=81385129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002812A PE20231941A1 (es) | 2021-04-06 | 2022-04-05 | Compuestos de oxoisoindolina sustituidos con piridinilo |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11718601B2 (es) |
| EP (1) | EP4320112A1 (es) |
| JP (1) | JP2024515243A (es) |
| KR (1) | KR20230165815A (es) |
| AR (1) | AR125298A1 (es) |
| AU (1) | AU2022253242A1 (es) |
| BR (1) | BR112023020077A2 (es) |
| CA (1) | CA3214244A1 (es) |
| CL (1) | CL2023002966A1 (es) |
| CO (1) | CO2023013321A2 (es) |
| IL (1) | IL307343A (es) |
| PE (1) | PE20231941A1 (es) |
| TW (1) | TW202304881A (es) |
| WO (1) | WO2022216644A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2070920B8 (en) | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| DE60231989D1 (de) | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL2559690T3 (pl) | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
| WO2007075598A2 (en) | 2005-12-20 | 2007-07-05 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP2064207B1 (en) | 2006-09-19 | 2013-11-06 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009137095A2 (en) | 2008-05-08 | 2009-11-12 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| JP5561577B2 (ja) | 2009-07-01 | 2014-07-30 | 国立大学法人 名古屋工業大学 | 光学活性３’−フルオロサリドマイド誘導体の製造方法 |
| ES2788869T3 (es) | 2009-09-03 | 2020-10-23 | Merck Sharp & Dohme | Anticuerpos anti-GITR |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| DK2949670T3 (da) | 2009-12-10 | 2019-05-13 | Hoffmann La Roche | Antistoffer, der fortrinsvis binder humant ekstracellulært CSF1R-domæne 4 og anvendelse deraf |
| PE20130479A1 (es) | 2010-03-04 | 2013-05-12 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos |
| EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| MX336682B (es) | 2010-03-05 | 2016-01-27 | Hoffmann La Roche | Anticuerpos contra csf-1r humanos y usos de los mismos. |
| NZ603193A (en) | 2010-05-04 | 2014-07-25 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
| MY162737A (en) | 2010-09-09 | 2017-07-14 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| JP6242804B2 (ja) | 2011-12-15 | 2017-12-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| AU2013308635A1 (en) | 2012-08-31 | 2015-03-12 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| EP3298004B1 (en) | 2015-05-22 | 2021-01-06 | Biotheryx Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| ES2862469T3 (es) | 2015-06-04 | 2021-10-07 | Arvinas Operations Inc | Moduladores de proteólisis a base de imidas y métodos de uso asociados |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| US11395820B2 (en) | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| WO2017185034A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (cdk8) by conjugation of cdk8 inhibitors with e3 ligase ligand and methods of use |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| AU2017326171B2 (en) | 2016-09-13 | 2021-12-09 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
| PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
| JP7286539B2 (ja) | 2016-11-01 | 2023-06-05 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化ｐｒｏｔａｃ、および関連使用方法 |
| RU2750484C2 (ru) | 2016-12-01 | 2021-06-28 | Эрвинэс Оперейшнс, Инк. | Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора |
| EP3559005A1 (en) | 2016-12-21 | 2019-10-30 | Biotheryx Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| CN110741004B (zh) | 2016-12-23 | 2023-10-17 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CN111629749A (zh) | 2017-10-18 | 2020-09-04 | 诺华股份有限公司 | 用于选择性蛋白质降解的组合物和方法 |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019241271A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Fused thiophene compounds |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020102195A1 (en) * | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
| KR20210129672A (ko) | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2020200291A1 (en) | 2019-04-02 | 2020-10-08 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
-
2022
- 2022-04-05 IL IL307343A patent/IL307343A/en unknown
- 2022-04-05 WO PCT/US2022/023387 patent/WO2022216644A1/en active Application Filing
- 2022-04-05 AU AU2022253242A patent/AU2022253242A1/en active Pending
- 2022-04-05 PE PE2023002812A patent/PE20231941A1/es unknown
- 2022-04-05 US US17/713,598 patent/US11718601B2/en active Active
- 2022-04-05 AR ARP220100840A patent/AR125298A1/es unknown
- 2022-04-05 BR BR112023020077A patent/BR112023020077A2/pt unknown
- 2022-04-05 EP EP22718513.9A patent/EP4320112A1/en active Pending
- 2022-04-05 KR KR1020237037708A patent/KR20230165815A/ko unknown
- 2022-04-05 TW TW111112957A patent/TW202304881A/zh unknown
- 2022-04-05 JP JP2023561684A patent/JP2024515243A/ja active Pending
- 2022-04-05 CA CA3214244A patent/CA3214244A1/en active Pending
-
2023
- 2023-06-08 US US18/331,348 patent/US20230303527A1/en active Pending
- 2023-10-04 CL CL2023002966A patent/CL2023002966A1/es unknown
- 2023-10-05 CO CONC2023/0013321A patent/CO2023013321A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220324840A1 (en) | 2022-10-13 |
| WO2022216644A1 (en) | 2022-10-13 |
| AR125298A1 (es) | 2023-07-05 |
| CL2023002966A1 (es) | 2024-02-23 |
| KR20230165815A (ko) | 2023-12-05 |
| AU2022253242A1 (en) | 2023-11-23 |
| CO2023013321A2 (es) | 2023-10-19 |
| EP4320112A1 (en) | 2024-02-14 |
| US11718601B2 (en) | 2023-08-08 |
| TW202304881A (zh) | 2023-02-01 |
| BR112023020077A2 (pt) | 2023-11-14 |
| JP2024515243A (ja) | 2024-04-08 |
| CA3214244A1 (en) | 2022-10-13 |
| US20230303527A1 (en) | 2023-09-28 |
| IL307343A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231207A1 (es) | Derivados indolicos como inhibidores de ras en el tratamiento del cancer | |
| PE20201202A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
| PE20221264A1 (es) | Inhibidores de egfr | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| PE20191260A1 (es) | Compuestos inhibidores del vih | |
| PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20210129A1 (es) | Compuestos de 4-azaindol | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| BRPI0507065A (pt) | derivados de quinolina e seu uso como inibidores micobacterianos | |
| PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| PE20191020A1 (es) | Compuestos quimicos | |
| PE20091524A1 (es) | Derivados de 2-aminopirimidina | |
| PE20210184A1 (es) | Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon | |
| PE20191486A1 (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER | |
| PE20231941A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| PE20210417A1 (es) | Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende |